CONTEXT 64
The prevalence of subclinical hypothyroidism (SHypo) reaches up to 10% in the elderly population, while 65 subclinical hyperthyroidism (SHyper) has a prevalence of 2.4%, and 4.3% in the population aged ≥80 66 years.
1,2 SHypo is biochemically defined as elevated serum thyroid-stimulating hormone (TSH, thyrotro-67 pin) levels, but free thyroxin (fT4) levels within laboratory reference ranges 3 , SHyper is defined as de-68 creased serum TSH concentrations and normal fT4 and fT3 levels. The subclinical forms of thyroid dys-69 function have previously been associated with increased risk of heart failure and coronary heart disease. [4] [5] [6] 70 Furthermore, SHyper may negatively influence bone and mineral metabolism. 
71
While both overt hyper-and hypothyroidism are known to lead to cognitive impairment and clinical 72 guidelines recommend screening for thyroid dysfunction among patients with cognitive disorders 8 , data on 73 the association between subclinical thyroid dysfunction (SCTD) and cognitive function remained conflict-74 ing. In the general population, the prevalence of mild cognitive impairment is 3-22%, with a higher preva-75 lence among adults >70 years (14-18%). [9] [10] [11] Mild cognitive impairment, a cognitive decline not normal for 76 age but with essentially preserved functional activities, is believed to be the earliest clinical symptom of 77 cognitive disorders and may be the stage to intervene with preventive therapies. 11, 12 The progression rate 78 from cognitive impairment to dementia in the general population aged > 65 years is around 6-10% per 79 year. 11 SHyper has also been associated with increased risk of dementia, 13 with one retrospective cohort 80 reporting a hazard ratio of 1.6 (95% confidence interval [CI] 1.2-2.3) for dementia.
14 SHypo might also be 81 associated with alterations in cognitive function, 13, 15, 16 with one case-control study reporting a nearly 4-82 fold increase in the odds ratio of dementia (OR=3.8, 95%CI 1.6-9.1). 17 
83
However, data on the association between SCTD and cognitive function are conflicting.
18-20

84
Two recent meta-analyses yielded discrepant findings for SHypo, one showing a significant risk of cogni-85 tive alteration (composite endpoint of reduced Mini-Mental State Examination (MMSE), Wechsler 86
Memory Scale-Revised, total memory quotient and Wechsler Adult Intelligence Scale scores) for SHypo 87 individuals younger than 75 years with an OR of 1.56 (95%CI 1.07-2.27), 21 whereas the other found no 88 6 reported other scales than MMSE. For our analyses, we also collected information on clinical dementia 121 (Supplement table 1 ). Additionally, we gathered data on MMSE results at baseline and follow-up visits 122 123
Data Extraction and Quality Assessment 124
Standardized data extraction forms were used to collect information from the included cohorts concerning 125 patient characteristics, thyroid hormone levels, and scales for tests or criteria used to define memory func-126 tion, dementia or Alzheimer's disease (AD). Data were extracted by one reviewer (CR) and verified by a 127 second independent reviewer (DS). Discrepancies were solved by a third author (NR). Two reviewers 128 (CR, DS) independently assessed study quality using key indicators of cohort study quality 24, 25 : origin of 129 population (convenience versus population-based, the latter defined as a random sample of the general 130 population), methods of outcome ascertainment and adjudication (considered as adequate if in each poten-131 tial case performed by an expert panel blinded regarding the thyroid status and following defined outcome 132 criteria), completeness of follow-up, assessment of the proportional hazard assumption and adjustment for 133
confounders. 134 135
Data Synthesis and Statistical Analysis 136
We expressed the estimates of the association between SCTD (i.e. SHyper or SHypo) and outcomes as 137 risk ratios (RR) for dementia or as between-group differences in mean changes from baseline for MMSE 138 scores (MD). Only prospective data were analyzed. A RR>1 indicates a higher risk of an event in SCTD 139 compared to euthyroids and a MD>0 indicates higher decline of MMSE in SCTD compared to euthyroids. 140
To account for the different lengths of follow-up time across studies, we standardized MD per 1 year unit. 141
We used most adjusted estimates provided by the studies as primary analysis. We used an inverse variance 142 random-effects meta-analysis to pool estimates across studies. Estimates of the association between SCTD 143 and dementia were pooled on a log scale and latter exponentiated to be reported as RR. To evaluate heter-144 ogeneity across the studies, we used the Q statistic with a conservative p-value of 0.10. 26 Furthermore, we 145 calculated the I 2 statistic, indicating the proportion of variability in estimates of effects across studies that7
is not due to chance alone (<25% low, 25-75% increasing, >75% high heterogeneity between studies).
24
147
We visually evaluated publication bias through funnel plots and, statistically, with the Egger's test. 27, 28 To 148 explore the sources of heterogeneity, we conducted several sensitivity analyses. Due to the small number 149 of studies in each group, subgroup analysis with interaction tests could not be meaningfully performed. 150
All P-values were two-sided. All analyses were conducted using STATA software, version 13.1 (College 151 Station, Texas). 152 8
RESULTS
153
Study Selection 154
Of the 1505 reports initially identified, 1471 remained after removing duplicates. We excluded 1435 rec-155 ords on the basis of their abstracts and 25 after full text examination (Figure 1) . Eleven studies met pre-156 specified eligibility criteria and were included in the analyses. The agreement among the reviewers was 157 98.63% for the first screen of abstracts (κ=0.75) and 89.74% for the full-text search (κ=0.71). 158
159
Study Characteristics 160
Eleven cohorts reported data on 16,805 participants (Table 1) . Two cohorts only included men. 29, 30 Mean 161 age was 70 years or higher, except for one study. 31 The follow-up time ranged from 12 to 152 months 162 (median follow-up 44.4 months). Eight cohorts excluded participants treated with thyroid hormones or 163 medications altering thyroid hormone levels, while three excluded the participants taking thyroid hor-164 mones or thyroid altering medication in sensitivity analysis.
32-34
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Description and Quality of Studies 167
The quality of studies was heterogeneous. Nine cohorts were population-based and two were convenience 168 samples (Supplement Table 1 ). All the cohorts used third generation TSH assays, except one using sec-169 ond generation tests and one that did not report test details. 35, 36 Four studies had a formal adjudication 170 committee for dementia diagnosis. [29] [30] [31] [32] Seven studies provided information on attrition during follow-171 up. 20, 29, 30, 32, 33, 36, 37 Six studies provided information on non-violation of the proportional hazard 172 assumption. 29, 30, 33, 34, 37, 38 All studies reported adjusted data with various confounders, except one study that 173 provided us unadjusted data. 
Subclinical Hyperthyroidism and Dementia 176
Among five cohorts analyzing the association between SHyper and dementia (n=6410, 329 cases of de-177 mentia, mean follow-up 68.3 months), [29] [30] [31] 37, 38 the pooled risk ratio [RR] of dementia was 1.67 (95%CI9 1.04-2.69, I 2 =0.0%, p for heterogeneity=0.82) among SHyper patients compared with euthyroidism (Fig-179 ure 2). Sensitivity analyses (Table 2 ) excluding one study with a convenience-based sample, one study 180 that followed both patients with and without thyroid hormone replacement, or studies without or not re-181 ported formal adjudication for dementia, yielded similar results. As the Framingham study only analyzed 182 the relationship with dementia using TSH tertiles (highest tertile: TSH 1.9-9.9 mU/L) and did not measure 183 fT4, 34 20, 31, 33, 36, 37 the pooled mean MMSE decline in cognitive function per year was 0.01 points 206 difference from baseline (95%CI -0.14-0.15; I 2 =23.5%, p for heterogeneity=0.27; Supplement Figure 1) . 207
Results remained similar after excluding one study using a convenience-based sample or one study that 208 followed both patients with and without thyroid hormone replacement (Supplement Table 2 Table 2 ) excluding one study with a conven-219 ience-based sample, studies using TSH cut-offs <4.5mU/l, one study that followed both patients with and 220 without thyroid hormone replacement, one study that might have subclinical hyperthyroid participants in 221 the control group, 35 or one study using unadjusted data yielded similar results. 222
223
Publication bias 224
Both graphical inspection and Egger's tests indicated little evidence of publication bias for all associa-225 tions, although the number of available studies was small (Supplement Figure 2) . 
DISCUSSION AND CONCLUSION 228
In this meta-analysis of 11 prospective cohorts, we found that SHyper, but not SHypo, might be associated 229 with an elevated risk for dementia, while decline in MMSE over time was minimal for both conditions. 230
SHyper showed also a similar pattern of higher risk for AD. Results for the association between SHyper 231 and dementia remained similar when we pooled higher quality studies in sensitivity analysis, such as stud-232 ies with formal adjudication process for the outcome assessment or population-based studies. 233
Our results for SHyper and risk for dementia are consistent with a non-systematic literature review sum-234 marizing results from 13 cross-sectional or case-control, and 10 cohort studies that found supportive evi-235 dence of an association between SHyper and cognitive impairment or dementia. 40 Of these 10 cohort stud-236 ies, four did not meet the eligibility criteria for our systematic review: one due to missing subgroups of 237 thyroid dysfunction 41 hazard ratio for dementia of 1.79 (95%CI 1.28-2.51), and a cross-sectional study found a positive associa-241 tion between SHyper and dementia in 1276 participants (33 with SHyper) aged >65 years (OR for demen-242 tia 4.1, 95%CI 1.3-13.1).
14,44 Van Osch et al prospectively studied 178 patients with AD and 291 commu-243 nity-dwelling controls without objective cognitive impairment, and found an adjusted OR for AD of 2.36 244 (95%CI 1.19-4.67) in participants in the lowest (TSH<1.3mU/l) versus highest TSH tertile 245 (TSH>2.1mU/l). 45 Another population-based prospective cohort of 313 elderly adults with normal TSH 246 that found that those with a decline of cognitive dysfunction had a mean TSH of 1.78mU/l, while those 247 without decline had a mean TSH of 2.24mU/l (p=0.001). 46 
249
Our findings might be consistent with the hypothesis that SHyper increases the risk of dementia, although 250 decline in MMSE over time did not differ between SHyper and euthyroidism. In our meta-analysis, only 251 two out of 11 studies published results on both dementia and MMSE in SHyper. Analyzing only these two 252 studies showed no larger decline of MMSE among participants with SHyper. This discrepancy might be 253 explained by several factors: the length of follow-up of studies on SCTD and dementia was twice the du-254 ration of studies on SCTD and MMSE (mean follow-up time 66 vs. 33 months), different population in-255 vestigated, the modest sensitivity of MMSE as a diagnostic tool (79%) 47, 48 , as well as for detecting mild 256 cognitive impairment and subtle changes in specific cognitive domains, and the multimodal approach 257 needed to diagnose dementia. 49 Furthermore, different scores were used as gold standard depending on the 258 type and version of diagnostic criteria (supplement table 1). Factors increasing the plausibility of the 259 association between SHyper and dementia were that results remained similar when we pooled higher qual-260 ity studies in sensitivity analysis, such as studies with formal adjudication process for the outcome as-261 sessment or population-based studies, and that SHyper also showed a pattern of higher risk for AD. How-262 ever, higher quality studies are needed. 263
264
Several pathways could explain the association of thyroid dysfunction with cognition and dementia. Thy-265 roid hormone has distinct effects on the cardiovascular system and thyroid dysfunction has been associat-266 ed with several cardiovascular risk factors, including hypertension, dyslipidemia and atrial fibrillation.
4,6
267
In turn, these cardiovascular risk factors are associated with a higher risk of dementia and Alzheimer's 268
Disease.
50 Most studies included in our meta-analysis adjusted for cardiovascular risk factors. However, 269 the number and type of variables that were adjusted for differed for each study. Other explanations for the 270 association include direct effects of thyroid hormone, such as neurotoxicity and altered gene expression in 271 pathways relevant for dementia. The exact pathophysiological link between thyroid dysfunction and de-272 mentia remains unclear and requires more research. 273
274
Recently, two meta analyses on SHypo and cognitive impairment were published, yielding discrepant 275 results. 21, 22 The first review included 13 studies and found a significant higher risk for cognitive alteration 276 (composite endpoint of incidence or prevalence of dementia or difference in MMSE, Wechsler Adult In-277 telligence scale and Wechsler Memory-Revised score) in SHypo individuals younger than 75 years (OR 278 1.56; 95%CI 1.07-2.27, p=0.02), and for dementia (OR 1.81; 95%CI 1.43-2.28, p<0.01).
21 However, the 279 authors pooled different designs (cross sectional, case-control, cohort studies), used a composite endpoint 280 of clinical events and scales as primary outcome, and found a significant risk for the primary endpoint 281 only in subclinical hypothyroid individuals younger than 75 years. As results were calculated on the basis 282 of mean age, without availability of individual patient data, they may have been subject to potential ag-283 gregation bias (ecological fallacy). 51 Contrary to that meta-analysis, all studies in our meta-analysis but 284 one (included only in a sensitivity analysis) measured fT4 to define SCTD. The second meta-analysis ana-285 lyzed 15 studies (9 cross-sectional, 6 prospective cohort studies) and found no association between SHypo 286
and decline in cognitive function among people aged > 60 years (cross-sectional analysis: pooled ES for 287 ] of <0.001%), 22 which is consistent 289 with our findings. In comparison to these two meta-analyses, we included only prospective cohorts (n=11) 290 allowing us to reduce the bias that could arise due to differing study designs. In order to broaden ourTo 291 make literature search broad enough, we excluded studies examining solely participants with overt thyroid 292 disease but added no other exclusion criteria. 293
Two small placebo controlled trials (n=89; n=94) found no evidence that treatment of SHypo with levo-294 thyroxin was associated with improved cognitive function.
18,52 However, these trials had several limita-295 tions. In the trial by Parle et al, 52 recruitment was based on a single thyroid function test, so that euthyroid 296 participants with transiently elevated TSH may have been included (50% in the placebo group were eu-297 thyroid at 12 months), which may have underpowered the trial to detect an effect of hormone 298 replacement.
52 Thyroxin substitution lasted only for 12-months, which may have been too short to affect 299 cognitive function. In the trial by Jorde et al, 18 one third of participants did not attend follow-up. Because 300 of numerous exclusion criteria, the study population was unusually healthy, with 57% of the participants 301 having a TSH value between 3.50 and 4.99mU/l, so that it probably included many euthyroid participants. 302
The ongoing TRUST (Thyroid Hormone Replacement for Subclinical Hypothyroidism) trial (ClinicalTri-303 als.gov: NCT01660126) may clarify whether treatment with levothyroxin in SHypo is associated with 304 better cognitive outcomes over time. 
305
There are several strengths of our meta-analysis. By combining the results of 11 prospective cohorts, we 306 analyzed a total of 432 cases of dementia and 160 cases of AD in more than 15,000 participants. By con-307 tacting several authors of these studies, we obtained additional data that allowed us to derive more uni-308 form subgroup and sensitivity analyses. In comparison to the two other meta-analyses, 21,22 our results are 309 less prone to bias due to pooling of heterogeneous study design and quality, because we only included 310 prospective cohorts. We also conducted a detailed literature search in several electronic databases with as 311 few limitations as possible in order to retrieve the maximum number of studies available on the topic, and 312
were able to include a larger number of prospective cohorts than previous meta-analyses.
21,22
314
Our meta-analysis has also several limitations. Except for two studies 30, 35 , studies only examined Cauca-315 sians, limiting the generalizability to other populations. All studies were performed in participants with a 316 mean age >65 years and the time of follow-up was relatively short, ranging between 12 and 70.8 months 317 318 studies assessed thyroid function tests only at baseline, which is a limitation of most previously published 319 large cohort studies on the risks of thyroid dysfunction 54, 55 . Some participants with SCTD at baseline may 320 have normalized to euthyroidism or progressed to overt thyroid disease over time. Regarding the elderly 321 participants in the included studies, we cannot exclude a certain degree of some overdiagnosis with of 322 SHypo due to the physiological rise of TSH towards upper limits during normal ageing 56 . All these non-323 differential misclassification of thyroid status might bias the results towards no difference. The limited 324 sensitivity of MMSE to for detecting subtle changes in specific cognitive domains 57 , may further limit our 325 ability to detect verify a possible decline in cognitive function. A meta-analysis of observational studies 326 requires cautious interpretation of the results and potential biases, and confounding and heterogeneity 327 must be carefully investigated. 58, 59 The quality of the incorporated studies was variable. We performed 328 several sensitivity analyses to address differences between the studies, as recommended, 58 although they 329 should be interpreted with caution given the small number of studies. In study level meta-analysis, inter-330 pretation of subgroup data should be performed with caution. Because of the small amount of studies, no 331 meaningful subgroup analysis could be performed in this study. There are multiple confounders for cogni-332 tive decline and dementia, the most important is age, others are depression or cardiometabolic risk factors. 333
All cohorts adjusted for age and several other confounders, but there was heterogeneity in the choice of 334 confounders, which may lead to residual confounding. Bias in the selection of included studies cannot be 335 excluded. To limit selection bias, we conducted a detailed literature search in several electronic databases 336 with broad inclusion. We performed graphical and statistical assessment to assess selective reporting, but 337 these analyses were not very sensitive considering the small number of studies included. 25, 28 Although 338 included cohorts enrolled community-dwelling adults in ambulatory visits, who are therefore less likely to 339 have an acute disease, some participants with non-thyroidal illness may have been analyzed. Included 340 studies addressed this problem differently: Two repeatedly measured thyroid values 20, 33 , one assessed and 341 adjusted for rT3 (reverse triiodothyronine) 38 , and others adjusted for comorbidities. We cannot exclude 342 that some participants had nonthyroidal illness. 343
What are the potential clinical and research implication of our findings? Our data suggest that SHyper 344 might represent a potentially treatable risk factor for dementia. Given the relatively high prevalence of 345 both SCTD and cognitive dysfunction in the aging population, even a modest increase of dementia inci-346 dence among individuals with SCTD might have public health implications. Data on benefit of SCTD 347 treatment are scarce, therefore current guidelines do not recommend treatment for most adults with mild 348 SCTD (serum TSH 0.1-0.45mU/l or 4.5-10.0mU/l). 528 † median 529 ‡ The Framingham Study did not use TSH cut-offs for SCTD, but tertiles: tertile 1: 0.1-1.08mU/l for women, 0.10-0.90mU/l for men; tertile 2: 1.10-2.03mU/l for 530 women, 0.99-1.80mU/l for men; tertile 3: 2.10-9.90mU/l for women, 1.09-9.90mU/l for men. Therefore, this study could not be included in the meta-analysis 531 but was added to a sensitivity analysis. 532 § Due to additional unpublished data provided by the authors, the studies could be incorporated in the meta-analysis on SCTD and MMSE; unadjusted data.
533
|| Due to additional unpublished data provided by the authors, the study could be incorporated in the meta-analysis on SCTD and dementia. 540 ‡ Performed on data additionally provided by the author; we did not include these data in the main analysis, as they 541 examined different follow-up duration and were not based on peer-reviewed published results (the investigators sent us 542 these data separately) 543 § As the Framingham Study did not use TSH cut-off for SCTD, we compared lowest versus highest tertiles (lowest 544 tertile: 0.10-1.08 for women, 0.10-0.90 for men; highest tertile 2.10-9.90 for women, 1.90-9.90 for men). 
595
* unadjusted additional data has been used for this meta-analysis. The original study adjusted for age, sex, education, serum cholesterol, Geriatric Depression Scale Score,
596
BMI, hypertension, diabetes mellitus, history of cardiovascular disease, plasma total homocysteine. 597 ** No adjustment for age because of same aged cohort.
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